| NCT ID | NCT05592678 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Condition | Alzheimer's Disease (AD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-08-05 |
| Primary Completion | 2028-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-08-05 with a primary completion date of 2028-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are: * Can an intervention's outcome be better assessed by a latent variable ("δ") integrating cognitive performance with functional status? * Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity? * Can a latent variable, derived from information collected remotely from caregivers, preselect subjects most likely to respond to the intervention? * Is the effect of the intervention in fact medicated by changes in the targeted biomarker? In this case, the biomarker will be a latent variable derived from several proteins measured in blood (i.e., so-called "adipokines"). The intervention will be donepezil, a medication approved for the treatment of Alzheimer's Disease, but only recently associated with adipokine changes. Participants with cognitive impairment and their caregivers will be interviewed by telephone and those newly prescribed donepezil by their provider for cognitive impairment will be recruited and enrolled. On the basis of the caregiver's report, the cognitively impaired subjects will be assigned to two groups based on a prediction of their response to donepezil. Researchers will compare those groups to see if dementia severity, as measured by δ, improves in predicted responders, and whether the change in the d-score is mediated by changes in adipokines.
Eligibility Criteria
Inclusion Criteria: 1. Ambulatory outpatient volunteers with co-informants. 2. Aged 65-100 years 3. Clinical diagnosis of AD, or MCI. 4. Capacity to give informed consent. 5. GDS score (15 item) ≤ 8. 6. No significant visual or hearing impairments 7. Standardized dECog score between 1.0 and 5.0 relative to ADNI's cohort. Exclusion Criteria: 1. A history of psychosis, including visual hallucinations; 2. History or treatment for Parkinson's, or tremor, or Rapid Eye Movement (REM) behavior disorder; 3. History of bradycardia or syncopal events; 4. Treatment for cancer in the last 5 years (excluding skin cancers); 5. Major surgery in the last year; 6. Treatment for a seizure disorder with anticonvulsants; 7. Treatment for agitation or psychosis with neuroleptics (treatment of anxiety or insomnia allowed); 8. Current treatment with donepezil or any other AChEI or exposure within the last six months 9. With a recently started Donepezil Rx (\< 2 weeks), inability to stop Donepezil treatment for 14 days prior to study enrollment. 10. AChEI treatment not appropriate due to negative risk/benefit ratio based on medical Hx and symptoms during screening. Evaluated by PI and referring clinician. 11. Co-participation in another study that the PI feels would pose a safety risk or adversely affect data integrity of this study.
Contact & Investigator
Donald R. Royall, MD
PRINCIPAL INVESTIGATOR
University of Texas
Frequently Asked Questions
Who can join the NCT05592678 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, up to 100 Years, studying Alzheimer's Disease (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05592678 currently recruiting?
Yes, NCT05592678 is actively recruiting participants. Contact the research team at guesss@uthscsa.edu for enrollment information.
Where is the NCT05592678 trial being conducted?
This trial is being conducted at San Antonio, United States.
Who is sponsoring the NCT05592678 clinical trial?
NCT05592678 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Donald R. Royall, MD at University of Texas. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.